Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT04357756 Completed - Clinical trials for Advanced Solid Tumor

A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Start date: April 21, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in combination with Toripalimab. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 when administered in combination with Toripalimab to subjects with advanced solid tumors.

NCT ID: NCT04349267 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Start date: July 14, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

NCT ID: NCT04348916 Terminated - Breast Cancer Clinical Trials

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Start date: May 20, 2020
Phase: Phase 1
Study type: Interventional

ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with Liver Metastases of Solid Tumors. The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

NCT ID: NCT04338724 Completed - Clinical trials for Advanced Solid Tumor

A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors

Start date: December 27, 2019
Phase: Phase 1
Study type: Interventional

This is an open label, dose escalation phase I study to evaluate the clinical safety, tolerability in subjects with advanced solid tumors, and to establish the Maximum Tolerated Dose (MTD#, if any). This study is composed of two dose level: 1 and 3 mg/kg.

NCT ID: NCT04337463 Recruiting - Clinical trials for Advanced Solid Tumor

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

Start date: April 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single-arm study with dose-escalation and expansion phases to access ATG-008 combined with Toripalimab in patients with advanced solid tumors.

NCT ID: NCT04336098 Completed - Clinical trials for Advanced Solid Tumor

Study of SRF617 in Patients With Advanced Solid Tumors

Start date: March 16, 2020
Phase: Phase 1
Study type: Interventional

A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.

NCT ID: NCT04328740 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Phase 1 Study of Oral TP-1454

Start date: July 8, 2020
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.

NCT ID: NCT04324814 Completed - Clinical trials for Advanced Solid Tumor

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Start date: March 31, 2020
Phase: Phase 1
Study type: Interventional

This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.

NCT ID: NCT04322552 Completed - Clinical trials for Advanced Solid Tumor

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

Start date: March 12, 2020
Phase: Phase 1
Study type: Interventional

Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2#VEGFR-2#, Induces Transporter Pgp function in vitro. This study in patients with advanced cancer evaluated the effect of Apatinib on Transporter Pgp function by comparing the pharmacokinetics of Transporter Pgp-specific probe drugs in the presence and absence of Apatinib. The probes used Substrate Digoxin.

NCT ID: NCT04322006 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Start date: May 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a phase I/II study of single drug TJ004309 and Toripalimab combine treatment for Advanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension. The purpose of part A is to confirm the MTD or MED and the clinical dose. The purpose of part B is to observe the safety, effectiveness, Pharmacokinetics, pharmacodynamics and biomarker properties for effective subjects.